

Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

Cyclin D3 (DCS22) Mouse mAb

RRID:AB_2070801

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2936, RRID:AB_2070801

Antibody Information

URL: http://antibodyregistry.org/AB_2070801

Proper Citation: Cell Signaling Technology Cat# 2936, RRID:AB_2070801

Target Antigen: Ccnd3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: W, IHC-P. Consolidation on 11/2018: AB_10698739, AB_10841292, AB_2070801, AB_2314272.

Antibody Name: Cyclin D3 (DCS22) Mouse mAb

Description: This monoclonal targets Ccnd3

Target Organism: rat, mouse, human

Antibody ID: AB_2070801

Vendor: Cell Signaling Technology

Catalog Number: 2936

Record Creation Time: 20250820T031902+0000

Record Last Update: 20250820T155538+0000

Ratings and Alerts

- Used for immunocytochemistry by the Human Islet Research Network community.
Contact(s): [Peng Wang](#), [Andrew Stewart](#) - Human Islets Research Network

No alerts have been found for Cyclin D3 (DCS22) Mouse mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 33 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Mahmoud A, et al. (2025) Paired primary-metastasis patient-derived organoids and mouse models identify phenotypic evolution and druggable dependencies of peritoneal metastasis from appendiceal cancer. *bioRxiv : the preprint server for biology*.

Huang X, et al. (2025) CDK4/6 Inhibition Reverses MEIS2 Suppression of CRL4 CRBN to Enhance Immunomodulatory Drug Therapy in Multiple Myeloma. *bioRxiv : the preprint server for biology*.

House NC, et al. (2025) CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. *NPJ breast cancer*, 11(1), 135.

Hawsawi O, et al. (2025) Mitochondrial uncouplers inhibit oncogenic E2F1 activity and prostate cancer growth. *Cell reports. Medicine*, 6(1), 101890.

Tang J, et al. (2025) Targeting N-Myc in neuroblastoma with selective Aurora kinase A degraders. *Cell chemical biology*, 32(2), 352.

Ogawa A, et al. (2025) SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosis. *Molecular cell*, 85(5), 894.

Wang Q, et al. (2025) Shc1 cooperates with Frs2 and Shp2 to recruit Grb2 in FGF-induced lens development. *eLife*, 13.

Ullrich V, et al. (2024) KDM5B predicts temozolomide-resistant subclones in glioblastoma. *iScience*, 27(1), 108596.

Zhou H, et al. (2024) Neddylation and Its Target Cullin 3 Are Essential for Adipocyte Differentiation. *Cells*, 13(19).

Shin S, et al. (2023) mTOR inhibition reprograms cellular proteostasis by regulating eIF3D-mediated selective mRNA translation and promotes cell phenotype switching. *Cell reports*, 42(8), 112868.

Arora M, et al. (2023) Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity. *Cell*, 186(12), 2628.

Golkowski M, et al. (2023) Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity. *Molecular cell*, 83(5), 803.

Takahashi K, et al. (2022) TGF- β generates a population of cancer cells residing in G1 phase with high motility and metastatic potential via KRTAP2-3. *Cell reports*, 40(13), 111411.

Tan J, et al. (2022) Moderate heart rate reduction promotes cardiac regeneration through stimulation of the metabolic pattern switch. *Cell reports*, 38(10), 110468.

Fischer N, et al. (2021) A novel ligand of the translationally controlled tumor protein (TCTP) identified by virtual drug screening for cancer differentiation therapy. *Investigational new drugs*, 39(4), 914.

Zhao R, et al. (2020) Acetylshikonin suppressed growth of colorectal tumour tissue and cells by inhibiting the intracellular kinase, T-lymphokine-activated killer cell-originated protein kinase. *British journal of pharmacology*, 177(10), 2303.

Ramezani-Rad P, et al. (2020) Cyclin D3 Governs Clonal Expansion of Dark Zone Germinal Center B Cells. *Cell reports*, 33(7), 108403.

Xiong L, et al. (2020) LncRNA-Malat1 is Involved in Lipotoxicity-Induced β -cell Dysfunction and the Therapeutic Effect of Exendin-4 via Ptp1. *Endocrinology*, 161(7).

Xiao B, et al. (2020) Rheb1-Independent Activation of mTORC1 in Mammary Tumors Occurs through Activating Mutations in mTOR. *Cell reports*, 31(4), 107571.

Au CC, et al. (2020) Three-dimensional growth of breast cancer cells potentiates the anti-tumor effects of unacylated ghrelin and AZP-531. *eLife*, 9.